MINDCURE reports a net loss for the fiscal year of CAD$10.2 million as it prepares to deploy its iSTRYM digital therapeutics platform. Cash and equivalents of CAD$18.3 million.
Exploring the companies and themes that make up this emerging and exciting new sector
Seattle Should Decriminalize All Drugs, City Task Force On Overdose Crisis Recommends
In response to the Seattle City Council’s request for policy advice on how to curb overdose deaths, a local task force is recommending the widespread decriminalization of all drugs.
Kelsey Ramsden on MINDCURE iSTRYM Beta and Commercial Distribution
After our July interview with CEO Kelsey Ramsden about the company’s Ibogaine synthesis, August brought more exciting announcements for Mind Cure Health Inc.
Psychedelic Drug Industry Report Card For 2021
As investors look to fine-tune their portfolios after the summer, we review the psychedelic drug industry and public company performance in 2021.
Psychedelic Medicine: The Legal Disconnect Grows
Two billion treatable (but untreated) mental health disorders globally. Eight million preventable deaths per year. The medicines that can save these lives are still illegal.
MindMed Announces Collaboration With Forian To Advance Development Of Personalized Psychiatry For Anxiety Disorders
MindMed and Forian will collaborate on drug R&D via the real-world evidence (RWE) pathway to drug development.
Cannabis Firm Plans South Africa IPO, Magic Mushroom Expansion
Cilo Cybin Pharmaceutical Ltd. is considering an initial public offering in the next 12 months after becoming the first South African company to win the right to grow, process and package cannabis products.
Portland Activists Push To Decriminalize Psychedelics Cultivation, Gifting And Community Ceremonies
Portland, Oregon activists are mounting a push to have local lawmakers pass a resolution decriminalizing the cultivation, gifting and ceremonial use of a wide range of psychedelics.
Psychedelic Drug Patents: All Patents Are Not Created Equal
Patent protection is of critical importance to the emerging psychedelic drug industry. With two types of drug patents and much additional patentable IP, there is much for investors to learn.
Cybin Files Two Additional International Patent Applications in Support of the Company’s Research Phase Programs
Cybin files two new patent applications in support of its proprietary psychedelic compounds.
Mydecine Innovations Group signs five-year Master Collaboration Research Agreement with Johns Hopkins University School of Medicine
Mydecine signs a 5-year research agreement with Johns Hopkins University, with an initial focus on smoking cessation.
Optimi Health Clears Final Base Shelf Prospectus
Optimi Health announces it has filed a Final Shelf Prospectus.